drugset / Trial / NCT06243614
Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD
Phase 3
Recruiting
410 enrolled
Beijing Union Pharmaceutical Factory Ltd
R&G Pharma Studies Co.,Ltd. · collab
RandomizedFactorialQuadruple-blindTreatment
Summary
A placebo-controlled superiority design was used to evaluate the efficacy of 60-120 mg/ day of Buagafuran capsules in the treatment of GAD.
Timeline
- Start
- 2023-07-24
- Primary completion
- 2026-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buagafuran | Unknown | 60 mg | — |
| Subject | Buagafuran | Unknown | 120 mg | — |
| Comparator | Buspirone | Small molecule | 10 mg | — |
| Comparator | Buspirone | Small molecule | 20 mg | — |